• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Puma Biotechnology Inc - Common Stock (NQ:PBYI)

    3.055 -0.055 (-1.77%)
    Streaming Delayed Price Updated: 1:26 PM EDT, Aug 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 93,464
    Open 3.100
    Bid (Size) 3.050 (5)
    Ask (Size) 3.060 (8)
    Prev. Close 3.110
    Today's Range 3.030 - 3.100
    52wk Range 2.225 - 4.130
    Shares Outstanding 47,509,765
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire

    Performance

    YTD
    -2.1%
    -2.1%
    1 Month
    -14.9%
    -14.9%
    3 Month
    -0.8%
    -0.8%
    6 Month
    +0.5%
    +0.5%
    1 Year
    -14.8%
    -14.8%

    More News

    Read More
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports First Quarter Financial Results
    From Puma Biotechnology, Inc..
    Via Business Wire
    Earnings Scheduled For May 8, 2025
    Via Benzinga
    Earnings Scheduled For February 27, 2025
    Via Benzinga
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Third Quarter 2024 Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Puma Biotechnology, Inc.
    Via Business Wire
    Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
    From Puma Biotechnology, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga

    Frequently Asked Questions

    Is Puma Biotechnology Inc - Common Stock publicly traded?
    Yes, Puma Biotechnology Inc - Common Stock is publicly traded.
    What exchange does Puma Biotechnology Inc - Common Stock trade on?
    Puma Biotechnology Inc - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Puma Biotechnology Inc - Common Stock?
    The ticker symbol for Puma Biotechnology Inc - Common Stock is PBYI on the Nasdaq Stock Market
    What is the current price of Puma Biotechnology Inc - Common Stock?
    The current price of Puma Biotechnology Inc - Common Stock is 3.055
    When was Puma Biotechnology Inc - Common Stock last traded?
    The last trade of Puma Biotechnology Inc - Common Stock was at 08/01/25 01:26 PM ET
    What is the market capitalization of Puma Biotechnology Inc - Common Stock?
    The market capitalization of Puma Biotechnology Inc - Common Stock is 145.14M
    How many shares of Puma Biotechnology Inc - Common Stock are outstanding?
    Puma Biotechnology Inc - Common Stock has 145M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.